Actuate Therapeutics, Inc. (NASDAQ: ACTU) has closed a public offering of common stock and warrants, raising approximately $9.96 million in net proceeds. The company entered into an underwriting agreement with Newbridge Securities Corporation on October 26, 2026, to sell 30,985,900 shares of common stock and warrants to purchase up to 15,492,950 additional shares.
The offering priced at a combined public offering price of $0.71 per set of two shares of common stock and one accompanying warrant. The warrants have an exercise price of $0.45 per share and are exercisable immediately upon issuance, expiring five years after issuance. The company granted the underwriter a 45-day option to purchase up to 4,647,885 additional shares of common stock and warrants to purchase up to 2,323,942 shares of common stock.
On October 28, 2026, the offering closed. In addition to the common stock and warrants sold to the public, the company issued warrants to Newbridge Securities Corporation or its designees to purchase up to 3.5% of the shares sold in the offering. These warrants are exercisable at $0.44375 per share, commencing 180 days after the agreement date and expiring on October 26, 2031.
Actuate Therapeutics intends to use the net proceeds from the offering for working capital and general corporate purposes. The company is a clinical-stage biopharmaceutical firm focused on developing novel therapies for difficult-to-treat cancers, with its lead investigational drug being elraglusib.
